Class information for:
Level 1: NIMOTUZUMAB//CETUXIMAB//EGFR

Basic class information
Class id #P Avg. number of
references		 Database coverage
of references
4440 1785 49.8 85%


Bar chart of Publication_year

Last years might be incomplete

Hierarchy of classes
The table includes all classes above and classes immediately below the current class.


Cluster id Level Cluster label #P
0 4 BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY 4064930
317 3       HER2//TRASTUZUMAB//CHRONIC MYELOID LEUKEMIA 39408
652 2             HER2//TRASTUZUMAB//HER 2 NEU 13568
4440 1                   NIMOTUZUMAB//CETUXIMAB//EGFR 1785

Terms with highest relevance score


rank Term termType Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 NIMOTUZUMAB authKW 626715 3% 62% 59
2 CETUXIMAB authKW 367682 10% 12% 186
3 EGFR authKW 335278 18% 6% 326
4 EPIDERMAL GROWTH FACTOR RECEPTOR authKW 248324 13% 6% 232
5 ZD1839 authKW 235793 2% 48% 29
6 RADIOBIOL MOL ENVIRONM address 147809 1% 39% 22
7 C225 authKW 124133 1% 48% 15
8 GEFITINIB authKW 114228 6% 7% 100
9 ONCOPHARMACOL UNIT address 104777 1% 26% 24
10 H R3 authKW 100609 1% 59% 10

Web of Science journal categories


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with term
in class
1 Oncology 35177 71% 0% 1275
2 Radiology, Nuclear Medicine & Medical Imaging 971 10% 0% 181
3 Otorhinolaryngology 549 4% 0% 73
4 Pharmacology & Pharmacy 298 10% 0% 180
5 Dentistry, Oral Surgery & Medicine 283 4% 0% 66
6 Cell Biology 114 6% 0% 111
7 Medicine, Research & Experimental 106 4% 0% 73
8 Pathology 40 2% 0% 37
9 Biotechnology & Applied Microbiology 15 3% 0% 51
10 Respiratory System 5 1% 0% 19

Address terms


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 RADIOBIOL MOL ENVIRONM 147809 1% 39% 22
2 ONCOPHARMACOL UNIT 104777 1% 26% 24
3 CATTEDRA ONCOL MED 60494 1% 14% 26
4 DIPARTIMENTO ENDOCRINOL ONCOL MOL CLIN 51345 1% 12% 26
5 POLE MIRO 45610 0% 67% 4
6 TUMOR BIOL METASTASIS GRP 45610 0% 67% 4
7 MCELWAIN S 36447 1% 24% 9
8 CONSORTIUM PHASE 2 34210 0% 100% 2
9 MED ONCOL HEAD NECK SURG 34210 0% 100% 2
10 SALICK HLTH CARE INC 34210 0% 100% 2

Journals


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 CLINICAL CANCER RESEARCH 15686 7% 1% 117
2 ORAL ONCOLOGY 11430 3% 1% 45
3 RADIOTHERAPY AND ONCOLOGY 7123 3% 1% 50
4 TARGETED ONCOLOGY 5941 1% 3% 12
5 SEMINARS IN ONCOLOGY 5199 2% 1% 40
6 HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK 4805 2% 1% 37
7 CANCER BIOLOGY & THERAPY 3770 1% 1% 25
8 MOLECULAR CANCER THERAPEUTICS 3490 2% 1% 29
9 INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS 3249 3% 0% 58
10 SEMINARS IN RADIATION ONCOLOGY 3082 1% 2% 12

Author Key Words


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class		 LCSH search Wikipedia search
1 NIMOTUZUMAB 626715 3% 62% 59 Search NIMOTUZUMAB Search NIMOTUZUMAB
2 CETUXIMAB 367682 10% 12% 186 Search CETUXIMAB Search CETUXIMAB
3 EGFR 335278 18% 6% 326 Search EGFR Search EGFR
4 EPIDERMAL GROWTH FACTOR RECEPTOR 248324 13% 6% 232 Search EPIDERMAL+GROWTH+FACTOR+RECEPTOR Search EPIDERMAL+GROWTH+FACTOR+RECEPTOR
5 ZD1839 235793 2% 48% 29 Search ZD1839 Search ZD1839
6 C225 124133 1% 48% 15 Search C225 Search C225
7 GEFITINIB 114228 6% 7% 100 Search GEFITINIB Search GEFITINIB
8 H R3 100609 1% 59% 10 Search H+R3 Search H+R3
9 EPIDERMAL GROWTH FACTOR RECEPTOR EGFR 88813 3% 10% 50 Search EPIDERMAL+GROWTH+FACTOR+RECEPTOR+EGFR Search EPIDERMAL+GROWTH+FACTOR+RECEPTOR+EGFR
10 OSI 774 86586 1% 56% 9 Search OSI+774 Search OSI+774

Core articles
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c:
(1) Number of references referring to publications in the class.
(2) Share of total number of active references referring to publications in the class.
(3) Age of the article. New articles get higher score than old articles.
(4) Citation rate, normalized to year.


Rank Reference # ref.
in cl.		 Shr. of ref. in
cl.		 Citations
1 UGURLUER, G , OZSAHIN, M , (2014) EARLY INVESTIGATIONAL DRUGS THAT TARGET EPIDERMAL GROWTH FACTOR RECEPTORS FOR THE TREATMENT OF HEAD AND NECK CANCER.EXPERT OPINION ON INVESTIGATIONAL DRUGS. VOL. 23. ISSUE 12. P. 1637 -1654 61 56% 1
2 HARARI, PM , HUANG, SM , (2004) COMBINING EGFR INHIBITORS WITH RADIATION OR CHEMOTHERAPY: WILL PRECLINICAL STUDIES PREDICT CLINICAL RESULTS?.INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. VOL. 58. ISSUE 3. P. 976-983 43 96% 39
3 HARARI, PM , (2004) EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITION STRATEGIES IN ONCOLOGY.ENDOCRINE-RELATED CANCER. VOL. 11. ISSUE 4. P. 689-708 48 67% 186
4 CIARDIELLO, F , TORTORA, G , (2001) A NOVEL APPROACH IN THE TREATMENT OF CANCER: TARGETING THE EPIDERMAL GROWTH FACTOR RECEPTOR.CLINICAL CANCER RESEARCH. VOL. 7. ISSUE 10. P. 2958 -2970 37 67% 666
5 BOSSI, P , RESTEGHINI, C , PAIELLI, N , LICITRA, L , PILOTTI, S , PERRONE, F , (2016) PROGNOSTIC AND PREDICTIVE VALUE OF EGFR IN HEAD AND NECK SQUAMOUS CELL CARCINOMA.ONCOTARGET. VOL. 7. ISSUE 45. P. 74362 -74379 55 54% 0
6 SACCO, AG , WORDEN, FP , (2016) MOLECULARLY TARGETED THERAPY FOR THE TREATMENT OF HEAD AND NECK CANCER: A REVIEW OF THE ERBB FAMILY INHIBITORS.ONCOTARGETS AND THERAPY. VOL. 9. ISSUE . P. 1927 -1943 48 53% 2
7 SUNDVALL, M , KARRILA, A , NORDBERG, J , GRENMAN, R , ELENIUS, K , (2010) EGFR TARGETING DRUGS IN THE TREATMENT OF HEAD AND NECK SQUAMOUS CELL CARCINOMA.EXPERT OPINION ON EMERGING DRUGS. VOL. 15. ISSUE 2. P. 185 -201 58 55% 19
8 SCHMITZ, S , ANG, KK , VERMORKEN, J , HADDAD, R , SUAREZ, C , WOLF, GT , HAMOIR, M , MACHIELS, JP , (2014) TARGETED THERAPIES FOR SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK: CURRENT KNOWLEDGE AND FUTURE DIRECTIONS.CANCER TREATMENT REVIEWS. VOL. 40. ISSUE 3. P. 390-404 61 41% 26
9 MENDELSOHN, J , BASELGA, J , (2003) STATUS OF EPIDERMAL GROWTH FACTOR RECEPTOR ANTAGONISTS IN THE BIOLOGY AND TREATMENT OF CANCER.JOURNAL OF CLINICAL ONCOLOGY. VOL. 21. ISSUE 14. P. 2787-2799 37 55% 803
10 BERNIER, J , BENTZEN, SM , VERMORKEN, JB , (2009) MOLECULAR THERAPY IN HEAD AND NECK ONCOLOGY.NATURE REVIEWS CLINICAL ONCOLOGY. VOL. 6. ISSUE 5. P. 266-277 56 50% 54

Classes with closest relation at Level 1


Rank Class id link
1 30546 NUCLEAR EGFR//EGFR FAMILY RECEPTORS//P TYR
2 2234 PANITUMUMAB//CETUXIMAB//KRAS
3 147 GEFITINIB//EGFR MUTATION//ERLOTINIB
4 11421 ANILINOQUINAZOLINE//4 ANILINOQUINAZOLINE//VEGFR 2 INHIBITOR
5 16698 TRICHOMEGALY//EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS//SKIN TOXICITY
6 17795 TCD50//TUMOR BED EFFECT//ONCORAY RADIAT
7 931 HEAD AND NECK CANCER//INDUCTION CHEMOTHERAPY//LARYNX PRESERVATION
8 6545 EGFRVIII//EGFR AMPLIFICATION//GLIOBLASTOMA
9 5515 TRANSFORMING GROWTH FACTOR ALPHA//TGF ALPHA//TGF ALPHA ASE
10 35026 M1B PROSTATE CANCER//BIOMARKER EPIDERMAL GROWTH FACTOR RECEPTOR EGFR//C ERB B 2 NEU GENE

Go to start page